Panmira appoints chief executive
Hari Kumar will oversee inflammation portfolio
Until recently, Kumar was chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.
Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb.
Kumar and his team will oversee Panmira's inflammation portfolio, which features a CRTH2 programme. The leading candidate, AM211, has demonstrated inhibition of eosinophils over 24 hours following oral, once-daily dosing in Phase I studies.
The firm says CRTH2 antagonists show promise for several diseases including eosinophilic esophagitis, eosinophilic asthma, COPD, and atopic dermatitis.
You may also like
Regulatory
Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria
Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)
With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Manufacturing
Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics
Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials